The Potential of Gene and Cell- Based Strategies for the Treatment of Osteogenesis Imperfecta - Osteogenesis Imperfecta - page 491

[3] Forlino A, Cabral WA, Barnes AM, Marini JC. New per-
spectives on osteogenesis imperfecta. Nat Rev Endocrinol
2011;7(9):540-57.
[4] Wilson JM. Medicine. A history lesson for stem cells. Science
2009;324(5928):727-8.
[5] Montiel-Equihua CA, Thrasher AJ, Gaspar HB. Gene therapy for
severe combined immunodeiciency due to adenosine deami-
nase deiciency. Curr Gene Ther 2012;12(1):57-65.
[6] Boye SE, Boye SL, Lewin AS, Hauswirth WW. A comprehensive
review of retinal gene therapy. Mol Ther 2013;21(3):509-19.
[7] Zhong L, Jayandharan GR, Aslanidi GV, Zolotukhin S, Herzog
RW, Srivastava A. Development of novel recombinant AAV vec-
tors and strategies for the potential gene therapy of hemophilia.
J Genet Syndr Gene Ther 2012:S1.
[8] Dong A, Rivella S, Breda L. Gene therapy for hemoglobinopa-
thies: progress and challenges. Transl Res 2013;161(4):293-306.
[9] Phillips MI. Gene, stem cell, and future therapies for orphan dis-
eases. Clin Pharmacol Ther 2012;92(2):182-92.

[23] Shaheen R, Alazami AM, Alshammari MJ, Faqeih E, Alhashmi N,

Mousa N, et al. Study of autosomal recessive osteogenesis imper-
fecta in Arabia reveals a novel locus deined by TMEM38B muta-
tion. J Med Genet 2012;49(10):630-5.

[24] Bodian DL, Madhan B, Brodsky B, Klein TE. Predicting the clini-

cal lethality of osteogenesis imperfecta from collagen glycine
mutations. Biochemistry 2008;47(19):5424-32.

[25] Marini JC, Forlino A, Cabral WA, Barnes AM, San Antonio JD,

Milgrom S, et al. Consortium for osteogenesis imperfecta muta-
tions in the helical domain of type I collagen: regions rich in
lethal mutations align with collagen binding sites for integrins
and proteoglycans. Hum Mutat 2007;28(3):209-21.

[26] Gioia R, Panaroni C, Besio R, Palladini G, Merlini G,

Giansanti V, et al. Impaired osteoblastogenesis in a murine
model of dominant osteogenesis imperfecta (OI), a new target
for OI pharmacological therapy. Stem Cells 2012;30(7):1465-76.

[27] Rowe DW, Shapiro JR, Poirier M, Schlesinger S. Diminished type I

collagen synthesis and reduced alpha 1(I) collagen messenger RNA
in cultured ibroblasts from patients with dominantly inherited
(type I) osteogenesis imperfecta. J Clin Invest 1985;76(2):604-11.

[10] Evans CH. Gene delivery to bone. Adv Drug Deliv Rev

2012;64(12):1331-40.

[11] Otsuru S, Gordon PL, Shimono K, Jethva R, Marino R, Phillips

CL, et al. Transplanted bone marrow mononuclear cells and
MSCs impart clinical beneit to children with osteogenesis imper-
fecta through different mechanisms. Blood 2012;120(9):1933-41.

[28] Stover ML, Primorac D, Liu SC, McKinstry MB, Rowe DW.

Defective splicing of mRNA from one COL1A1 allele of type I
collagen in nondeforming (type I) osteogenesis imperfecta.
J Clin Invest 1993;92(4):1994-2002.

[12] Niemansburg SL, van Delden JJ, Dhert WJ, Bredenoord AL.

Regenerative medicine interventions for orthopedic disor-
ders: ethical issues in the translation into patients. Regen Med
2013;8(1):65-73.

[29] Ben Amor IM, Roughley P, Glorieux FH, Rauch F. Skeletal

clinical characteristics of osteogenesis imperfecta caused by
haploinsuficiency mutations in COL1A1. J Bone Miner Res.
2013;28(7):1531-6.

[13] Gautieri A, Uzel S, Vesentini S, Redaelli A, Buehler MJ.

Molecular and mesoscale mechanisms of osteogenesis imper-
fecta disease in collagen ibrils. Biophys J 2009;97(3):857-65.

[30] Shapiro JR, Lietman C, Grover M, Lu JT, Nagamani SC, Dawson

BC, et al. Phenotypic variability of osteogenesis imperfecta
type V caused by an IFITM5 mutation. J Bone Miner Res
2013;28(7):1523-30. [14] Semler O, Garbes L, Keupp K, Swan D, Zimmermann K,

Becker J, et al. A mutation in the 5′-UTR of IFITM5 creates an in-
frame start codon and causes autosomal-dominant osteogen-
esis imperfecta type V with hyperplastic callus. Am J Hum Genet
2012;91(2):349-57.

[31] Walsh CE, Batt KM. Hemophilia clinical gene therapy: brief

review. Transl Res 2013;161(4):307-12.

[32] Whyte MP, Greenberg CR, Salman NJ, Bober MB, McAlister WH,

Wenkert D, et al. Enzyme-replacement therapy in life-threatening
hypophosphatasia. N Engl J Med 2012;366(10):904-13. [15] Cho TJ, Lee KE, Lee SK, Song SJ, Kim KJ, Jeon D, et al. A single

recurrent mutation in the 5′-UTR of IFITM5 causes osteogenesis
imperfecta type V. Am J Hum Genet 2012;91(2):343-8.

[33] Sugano H, Matsumoto T, Miyake K, Watanabe A, Iijima O,

Migita M, et al. Successful gene therapy in utero for lethal
murine hypophosphatasia. Hum Gene Ther 2012;23(4):399-406. [16] Bogan R, Riddle RC, Li Z, Kumar S, Nandal A, Faugere MC,

et al. A mouse model for human osteogenesis imperfecta type
VI. J Bone Mine Res. 2013;28(7):1531-6.

[34] Ferla R, O'Malley T, Calcedo R, O'Donnell P, Wang P, Cotugno G,

et al. Gene therapy for mucopolysaccharidosis type VI is effec-
tive in cats without pre-existing immunity to AAV8. Hum Gene
Ther 2013;24(2):163-9.

[17] Chang W, Barnes AM, Cabral WA, Bodurtha JN, Marini JC.

Prolyl 3-hydroxylase 1 and CRTAP are mutually stabilizing
in the endoplasmic reticulum collagen prolyl 3-hydroxylation
complex. Hum Mol Genet 2010;19(2):223-34.

[35] Eisengart JB, Rudser KD, Tolar J, Orchard PJ, Kivisto T, Ziegler

RS, et al. Enzyme replacement is associated with better cogni-
tive outcomes after transplant in Hurler syndrome. J Pediatr
2013;162(2):375-380 e1.

[18] Barnes AM, Carter EM, Cabral WA, Weis M, Chang W,

Makareeva E, et al. Lack of cyclophilin B in osteogenesis imperfecta
with normal collagen folding. N Engl J Med 2010;362(6):521-8. [36] Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A,

Morillon E, et al. Insertional oncogenesis in 4 patients after
retrovirus-mediated gene therapy of SCID-X1. J Clin Invest
2008;118(9):3132-42.

[19] Schwarze U, Cundy T, Pyott SM, Christiansen HE, Hegde MR,

Bank RA, et al. Mutations in FKBP10, which result in Bruck syn-
drome and recessive forms of osteogenesis imperfecta, inhibit
the hydroxylation of telopeptide lysines in bone collagen. Hum
Mol Genet 2013;22(1):1-17.

[37] O'Reilly M, Shipp A, Rosenthal E, Jambou R, Shih T,

Montgomery M, et al. NIH oversight of human gene transfer
research involving retroviral, lentiviral, and adeno-associated
virus vectors and the role of the NIH recombinant DNA advi-
sory committee. Methods Enzymol 2012;507:313-35.

[20] Christiansen HE, Schwarze U, Pyott SM, AlSwaid A, Al Balwi M,

Alrasheed S, et al. Homozygosity for a missense mutation in
SERPINH1, which encodes the collagen chaperone protein
HSP47, results in severe recessive osteogenesis imperfecta. Am J
Hum Genet 2010;86(3):389-98.

[38] Leath A, Cornetta K. Developing novel lentiviral vectors into

clinical products. Methods Enzymol 2012;507:89-108.

[21] Baron R, Kneissel M. WNT signaling in bone homeostasis

and disease: from human mutations to treatments. Nat Med
2013;19(2):179-92.

[39] Wilson JM. Lessons learned from the gene therapy trial for

ornithine transcarbamylase deiciency. Mol Genet Metab 2009;
96(4):151-7.

[22] Volodarsky M, Markus B, Cohen I, Staretz-Chacham O, Flusser H,

Landau D, et al. A deletion mutation in TMEM38B associated
with autosomal recessive osteogenesis imperfecta. Hum Mutat
2013;34(4):582-6.

[40] Romano G. Development of safer gene delivery systems to

minimize the risk of insertional mutagenesis-related malignan-
cies: a critical issue for the ield of gene therapy. ISRN Oncol
2012;2012:616310.